|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||1.29 - 1.30|
|52 Week Range||1.29 - 1.30|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Categories: Yahoo FinanceGet free summary analysis Merus Labs International, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Merus Labs International, Inc. – OncoMed Pharmaceuticals, Inc., Omeros Corporation and Onconova Therapeutics Inc. (OMED-US, OMER-US and ONTX-US) that have also reported for this period. Highlights Summary ... Read more (Read more...)
The approval marks the first time that an immunotherapy has been combined with another drug to kill cancer cells more effectively.
On a per-share basis, the Toronto-based company said it had a loss of 1 cent. The drugmaker posted revenue of $17.1 million in the period. The company's shares closed at 76 cents. A year ago, they were ...